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Ab t t H d I t
. I f I. k d I . I Among such carriers, uItralow-sized hydrogel nanoparticless rac y roge nanopar ICes 0 cross- m e po yvmy pyr- ..
rolidone (PVP-NP) (35-50 nm in diameter) containing fIuor- [2] made up of polyvmylpyrrolldone (PVP-~P) hav~ been se-
esceinated dextran (FITC-Dx) were encapsulated in ~ected as th~ pol~m~r component and are .hlghly blOcomp~t-
reconstituted Sendai viral envelopes containing only the fusion Ible [3]. Besides slgmficant progress made m the field of blO-
(F) protein (F-virosomesl). Incubation of these loaded F-viro- medical applications of nanotechnology, different factors
somes with human hepatoblastoma cells (HepG2) in culture (size, surface, cell-specific uptake of NPs and endosomal es-
'resulted in membrane-fusion-mediated delivery of NPs to the cell cape) associated with NP targeting of drugs could be pivotal
cytoplasm, as inferred from the ability of cells to internalize for a successful outcome [4]. While size surface and cell-spe-
FIT~-I?~ loaded PVP-NP (~VPf_NP) in the pres~nce of azi~e cific uptake of NPs have been resolved to some extent [1],
(an mhlbltor of the endocytotIc process). Introduction of PVP- existing technology fails to deliver drug-loaded NPs directly
NP into the HepG2 cells was assured by selective accumulation .. . .
f FITC fI
.
th t I
. t t Th mSlde the cytosol of deSIred cell types evadmg endosomalo uorescence m e cy oso IC compar men. e . ..
structural integrity of the internalized PVpf_NP was also pathway for It.Sexpected o~tllI~um actIOn [4]. In. the past
confirmed by fluorescence microscopy and ultracentrifugation few years, engmeered Sendal viral envelopes (F-vlrosomes)
analysis. The potential usefulnessof PVP-NP-mediated cytosolic are known to specifically bind and fuse efficiently with the
release of water soluble drugs both in Vitroand in vivo has been plasma membrane of hepatocytes both in vitro and in vivo
established for the first time. ,,-'~ ~ .-,!nd served as excellent carriers for fusion-mediated microin-
-, - . - - .. ~... . -i _.- -= _ "'5' - ;ttion of various biologically active molecules into their cy-
OL.,.. .' tosolic compartments [5-10].
, In the present study, PVP-NP of defined size (approxi-
mately 50 nm in diameter) loaded with fluorescein isothiocya-
nate dextran (FITC-Dx; model drug of choice) have been
entrapped within F-virosomes. We demonstrate that these
loaded F-virosomes (delivery vehicle inside a delivery vehicle)
fuse with HepG2 cell membranes and microinject the encap-
sulated FITC-Dx-loaded polyvinylpyrrolidone NP (PVpf_NP)
into the cell cytoplasm. The delivery of PVpf-NPs from viro-
somes to the cytosol of the target cells is reported for the first
time in a systematic and quantitative fashion. The efficacy of
this unique hybrid delivery system with respect to controlled
release of drugs inside the cytosolic compartment is discussed.
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1. Introduction
c:
Despite improvements in viral and non-viral vector systems,
a major hurdle in the delivery of drugs and other macromo-
lecules into the desired cell types is crossing the permeability
barrier imposed by the plasma membrane followed by the
controlled release inside the cytoplasm [1]. On the other
hand, it is known that controlled release of drugs can be
significantly improved by using nanoparticulate carriers [1].
*Corresponding author. Fax: (91)-11-6883283.
E-mail addresses:maitra@giasdlOl.vsnl.net.in(A.Maitra).
drcmg@pop3.satyam.net.in (C.M. Gupta), sarkar@deI3.vsnl.net.in
(D.P. Sarkar).
I Process for Producing a Targeted Gene (1997) US Patent 5, 683,
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Abbreviations:ASGP-R, asialoglycoprotein receptor; CHO, Chinese
hamster ovary; DMEM, Dulbecco's modified Eagle's medium;
DPBS, Dulbecco's phosphate-buffered saline; EDTA, ethylenediami-
netetraacetate (disodium salt); F, fusion protein; FCS, fetal calf se-
rum; FITC-Dx, fluorescein isothiocyanate dextran (mol wI. 19.3
kDa); PL, polylysine; PVpf_NP, FITC-Dx-Ioaded polyvinylpyrroli-
done nanoparticle; TBS, Tris-buffered saline
2. Materials and methods
2.1. Preparationof PVpf-NP
PVpf_NP were made following our previous communication [11]. In
brief, 40 ml of 0.03 M sodium bis-2-ethylhexylsulfosuccinate (AOT)
solution in hexane was taken and to it 280 IIIof freshly distilled vinyl
pyrrolidone, 50 IIIofN,N'-methylene bisacrylamide (0.049 glml), 20 III
N,N,N' ,N'-tetramethylethylenediamine ~nd 20 III of ammonium per-
sulfate (saturated solution) and 50 III (160 mglml in water) of FITC-
Dx (Sigma, St. Louis, MO, USA; mol. wI. 19.3 kDa) were added.
Polymerization was carried out at 37°C for 8 h with continuous stir-
ring. After the completion of the reaction the excess solvent (hexane)
was evaporated in a rotatory evaporator and the dry mass was resus-
pended in 10 ml of water by sonication. Then, I ml of 30% CaCh
solution was added dropwise with continuous stirring to precipitate
the AOT as calcium salt of bis (2-ethyl-hexyl) sulfosuccinate
(Ca(DEHSS)z) followed by dialysis against water. Ca(DEHSS)z was
separated by centrifugation. After separating the unentrapped FITC-
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Dx by gelfiltration, the supernatant containing Pypf_NP was lyophi-
lized to dry powder for subsequent use. The amount of FITC-Dx
entrapped inside PYP-NP was calculated (200 ~g of FITC-Dx/mg of
PVpf_NP) and their average diameter was determinedby electron
microscopy [2].
2.2. Preparation of PVpf-NP loaded F-virosomes
Reconstituted Sendai viral envelopes containing F-protein (F-viro-
some) were prepared as described earlier [5]. The Triton X-IOO (TX-
100)-solubilized fraction of virus was mixed with pypf -NP (500 ~g of
Pypf_NP/mg of viral protein) and reconstitutedby stepwise removal
of detergent using SM2 biobeads. The unentrapped Pypf_NP ad-
sorbed on the surface of virosomal membrane was removed by re-
peated washing with cold 0.01 M Tris-buffered saline (TBS), pH 7.4.
Furthermore, to remove the residual amount of aggregated form of
Pypf_NP and FITC-Dx adsorbed on the virosomal surface, the
loaded virosomes were subjected to sucrose density gradient ultracen-
trifugation following the protocol of Paternoster et al. [12]. The
amount of entrapped Pypf_NP was determinedby fluorescence mea-
surement at 490/520 nm (excitation/emission). FITC-Dx-Ioaded F-vi-
rosomes were made following our published procedure for entrapping
water soluble molecules [5,7]. Each preparation of such loaded viro-
somes was tested for both structure and function following our pub-
lished protocol [6].
2.3. Cells
HepG2 (human hepatoblastoma cells), NIH3T3 (mouse fibroblast)
and CHO (Chinese hamster ovary) cells were maintained in Dulbec-
co's modified Eagle's medium (DMEM) containing 10% fetal calf
serum (FCS), sodium pyruvate (110 ~g/ml), penicillin (100 U/ml)
and streptomycin (100 ~g/ml) under 5% C02. All cell culture reagents
were procured from Invitrogen, USA.
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2.4. Fusion-mediated delivery of PVPf-NP and FlTC-Dx into
HepG2 cells
2.4.1. Spectrojluorimetric measurements.Single cell suspensions of
HepG2 cells were madeby lifting the cells from monolayer with ethyl-
enediaminetetraacetate (EDT A) [7]. The cells were finally suspended
in DMEM without serum to obtain 1.0x 106 cells/ml. Loaded F-vi-
rosomes were incubated with cells with varying doses and time at
37°C. The virosome-cell mixtures were washed with cold Dulbecco's
phosphate-buffered saline (DPBS) containing 2 mM Ca2+ and 2 mM
Mg2+ thrice and finally incubated at 4°C for 10 min in DPBS con-
taining 5 mM EDTA to remove (EDT A-stripping) the cell surface-
bound (unfused) virosomes as standardized earlier [7].The cell pellets
after EDTA-stripping were solubilized in TBS containing 0.3% TX-
100 and fluorescence was measured with a spectrofluorometer (model
RF 540, Shimadzu Corp., Kyoto, Japan) at 490/520 nm (excitation/
emission) wavelength. Heat-treated F-virosomes (incubated at 56°C
for 20 min), F-virosomes incubated with NIH3T3 and CHO cells
and F-virosomes pre-incubated with mouse anti-F glycoprotein anti-
bodyraised in our laboratory [13]were taken as appropriate controls.
Fluorescence value of virosome-cell complex without EDTA-stripping
was used to calculate the percentage of internalization of PVpf_NP
and/or FITC-Dxby liver cells. Sodium azide is known to be an effi-
cient inhibitor of endocytosis process [14]. Binding and fusion of
virosomes and heat-treated virosomes with target cells were studied
in the presence of 10 mM azide as described earlier [6,7].
2.4.2. Fluorescence microscopy.Glass coverslips (Erie Scientific,
Portsmouth, NH, USA) were coated with polylysine (PL; Sigma,
USA) following standard protocol [15]. HepG2 cells were grown in
24-well plates (Becton Dickinson, Cockeysville, MD, USA) on PL-
coated coverslips and were incubated with either Pypf_NP or FITC-
Dx-Ioaded F-virosomes in DMEM without serum. HepG2 cells mixed
with heat-treated loaded F-virosomes were used as controls. The me-
dium was replaced after 2 h with DMEM containing 10% FCS and 10
mM sodium azide and was incubated inside a C02 incubator for
different times. At each time point coverslips were subjected to
EDTA-stripping and were mounted on glass slides with 10 ~I of
DMEM. Fluorescence was detected and images were recorded on
Kodak color film using an Eclipse TE 300 (Nikon, Japan) microscope.
The light source was a 100 W Hg lamp with appropriate levels of heat
and neutral density filters. The fluorescein filters were a standard
Nikon set, consisting of 490-nm excitation filter and a 520-nm emis-
sion filter. The camera system was from Nikon, Japan.
2.5. Cell fractionation
F-virosomes (pypf -NP or FITC-Dx loaded, untreated or heat-
treated in each case) were incubated with HepG2 cells in DMEM
without serum at 37°C for 2 h. After EDTA-stripping the cells were
washed thrice with TBS and were subjected to subcellular fractiona-
tion following our published procedure [7]. In brief, the cells were
resuspended in the isotonic homogenizing buffer (0.01 M Tris-HCI,
pH 7.4, containing 0.25 M sucrose) and then dispersed in a Potter-
Elvehjem type homogenizer at 4°C. Fluorescence associated with each
fraction was analyzed and expressed as percent of total amount of
fluorescence associated with the whole cells. PVpf-NPs are known to
be pelleted at 100000Xg for 4 h at 4°C without affecting their struc-
tural integrity (unpublished observation). Therefore, cytosolic frac-
tions obtained from subcellular fractionation of HepG2 cells were
further centrifuged at 100000xg for 4 h at 4°C with a view to sep-
arate the intact PVpf_NP from its degraded counterpart.
3. Results
3.1. Characterization of PVpf -NP loaded F-virosomes
The purity of F-virosome preparations was checked by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis in
the presence of p-mercaptoethanol [6] and was found to be
free from any contamination by other proteins. Membrane-
fusion activity of these loaded virosomes was ascertained by
their ability to hemolyze mouse red blood cells (RBCs) in the
presence of wheat germ agglutinin [6]. The entrapped PVpf_
NP was retained in intact form inside F-virosomes in the
presence of 10% FCS over a period of 48 h in contrast to
our earlier observations indicating the ability of serum pro-
teases in degrading free PVpf-NP [2]. 5-15 ~g of PVpf_NP
was encapsulated in I mg of F-virosomes whereas 40-60 ~g of
free FITC-Dx was entrapped per mg of F-virosomes. Electron
microscopy of PVpf-NP (data not shown) preparations and
negatively stained loaded virosomal suspension [16] revealed
their spherical shape with size varying between 35-50 nm and
100-200 nm in diameter respectively.
3.2. Internalization of PVpf-NP into HepG2 cells delivered
through F-virosomes
Our aboratory has pioneered the observation that F-viro-
somes can bind and fuse efficiently with HepG2 cells through
the interaction of terminal galactose of fusion with the asia-
80
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Fig. I. Dose-dependent internalization of PVpf_NP into HepG2 cells
delivered through F-virosomes. Different amounts (in terms of
F pr tein) of loaded F-virosomes, heat-treated F-virosomes or F-vi-
rosomes pre-incubated with anti-F antibody were incubated with
HepG2 cells in DMEM at 37°C for 2 h. Pypf-NP-associated
fluorescein with cells was determined after EDTA-stripping as de-
scribed on Section 2.4. Black bars, F-virosomes with HepG2 cells;
hatched bars, heat-treated F-virosomes with HepG2 cells; dotted
bars, F-virosomes pre-incubated with anti-F antibody. Each value is
mean of three independent determinations.
FEBS Lett.515,184-189 (2002)
100
20
o
o .
Time(hr)
Fig. 2. Kinetics of accumulation of PVpf_NP into HepG2 cells de-
livered through F-virosomes. Loaded F-virosomes (100 I-lg)were in-
cubated with 1.0x 106 HepG2 cells at 37°C for different times in
DMEM. The virosome-cell complexes were kept at 4°C for 10 min
in DPBS containing 5 mM EDTA to remove surface bound F-viro-
somes (unfused). After washing, the cell pellets were solubilized in
TBS containing 0.3% TX-IOO and fluorescence were measured with
a spectrofluorometer. Fluorescence unit without EDTA-stripping
was considered as 100%. ., F-virosomes with HepG2 cells in the
presence of azide;., heat-treated F-virosomes incubated with
HepG2 cells without azide; ..., heat-treated F-virosomes with
HepG2 cells in the presence of azide;., F-virosomes with NIH3T3
cells; 0, F-virosomes pre-incubated with anti-F antibody; 0, F-viro-
somes with CHO cells. The values are means of triplicate observa-
tions.
...
loglycoprotein receptors (ASGP-Rs) [5,7]. We have utilized
this system to explore the possibility of delivering PVpf-NP
of defined size to the cytosolic compartment of HepG2 cells.
Uptake of PVpf_NP by cells at 37°C was examined as a func-
tion of dose of F-virosomes. Fig. I shows a saturation type
curve representing cell-associated PVpf-NP. No increase of
PVpf-NP delivery was noticed beyond 100 J..lgof F-virosomes
and this was employed in all subsequent experiments. Figs. 2
and 3 demonstrate that the initial rate of delivery of PVpf-NP
to HepG2 cells through F-virosomes was twice that of FITC-
Dx in the presence of 10 mM sodium azide.
The subtle molecular mechanism associated with higher rate
of internalization of NP is yet to be understood. Correspond-
ing heat-treated loaded virosomes in the presence of 10 mM
azide revealed no internalization of entrapped PVpf-NP and
FITC-Dx. On the other hand, the heat-treated loaded viro-
somes were able to bind to HepG2 cells to the same extent as
that of untreated virosomes at 4°C (data not shown). Slight
internalization (ca. 10%) of both PVpf_NP and FITC-Dx ob-
served in the case of heat-treated F-virosomes and virosomes
pre-incubated with anti-F antibody may be due to the endo-
cytosis of bound non-fusogenic virosomes. Negligible fusion
Table I
Subcellular Localization of PVpf_NP inside HepG2 cells
Virosomes LysosomaUmitochondrial (%) Cytosol (%)
Experimental 27 61
Heat-treated 50 21
HepG2 (2.0x 106) cells were incubated with loaded F-virosomes or
heat-treated F-virosomes (200 I-lgF protein) in DMEM at 37°C for
2 h. The cells were EDTA-stripped and cell fractionation was car-
ried out as described in Section 2. Fluorescence unit without
EDTA-stripping was considered as 100%. Each value is the mean of
three independent experiments.
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Table 2
Integrity of PVpf_NP in the cytosolic fraction of HepG2 cells
Time (h) Supernatant (%) Pellet (%)
0.5 8 90
2 15 80
4 25 73
6 ~ ~
9 92 5
HepG2 (2.0x 106) cells were incubated with loaded F-virosomes
(200 I-lgF protein) in DMEM at 37°C over a period of 9 h as de-
scribed in Fig. 4. The cells were EDTA-stripped and cell fractiona-
tion was carried out as described in Section 2. The cytosolic frac-
tions were further subjected to ultracentrifugation at 100000 xg at
4°C for 4 h to separate the intact PVpf -NP (fluorescence value in
the pellet) from the degraded ones (fluorescence value in the super-
natant). Fluorescence unit of the total cytosolic fraction was consid-
ered as 100%, while calculating the percent fluorescence values.
Each value is the mean of three independent determinations.
activity ( < 2%) was obtained with NIH3T3 and CHO cells as
target. Taken together, these results strongly support target-
specific, membrane-fusion-mediated cytosolic delivery of
PVpf -NP by F-virosomes to the HepG2 cells.
3.3. Subcellular distribution patterns of PVpf -NP delivered by
F-virosomes and heat-treated F-virosomes: cytosolic
delivery of PVpf -NP
Table I shows that about 61% of the total cell-associated
fluorescence was recovered from cytosolic fraction using F-vi-
rosome as carrier. By contrast, 50% of the fluorescence was
recovered in lysosomal/mitochondrial fraction with a concom-
itant decrease (66%) in the cytosolic fluorescence in the case of
heat-treated F-virosomes. These results clearly support the
fusion-mediated delivery of PVpf-NP by F-virosomes to
HepG2 cells. Heat-treated F-virosomes being non-fusogenic
[5-7] are likely to be taken up by endocytosis leading to their
accumulation and subsequent degradation in Iysosomes. Ad-
ditionally, the integrity of the PVpf_NP inside the cytosol was
assessed directly by pelleting the NPs at higherg forc fol-
100
80
Fig. 3. Kinetics of accumulation of FITC-Dx into HepG2 cells
transferred through F-virosomes. Loaded F-virosomes (100 I-lg)were
incubated with 1.0x 106 HepG2 cells at 37°C for different times in
DMEM. For details about the incubation of virosomes and fluores-
cence measurements, see the legend to Fig. 2. ., F-virosomes with
HepG2 cells in the presence of azide;., heat-treated F-virosomes
incubated with HepG2 cells without azide; ..., heat-treated F-viro-
somes with HepG2 cells in the presence of azide;., F-virosomes
with NIH3T3 cells; 0, F-virosomes pre-incubated with anti-F anti-
body; 0, F-virosomes with CHO cells. The values are means of
triplicate recordings.
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lowed by estimating the associated fluorescence intensity (Ta-
ble 2).
3.4. Light microscopy of cytosolic delivery of PVpf -NP in
HepG2 cells
To provide direct proof in support of cytosolic localization
Panel A
O.Sh
O.Sh
(HC)
2h
4h
6h
9h
9h
(HC)
Panel B
Fig. 4. Controlled release of FITC-Ox from PVpf_NP into HepG2
cells. HepG2 cells were grown on PL-coated coverslips and were in-
cubated with PVpf_NP and FITC-Ox-loaded F-virosome separately
for different times from 0.5 to 9 h and photographed (magnification,
X40) as mentioned in Section 2. Panel A represents the cells deliv-
ered with PVpf_NP and panel B represents the cells delivered with
FITC-Ox through F-virosomes. -> denotes the punctate nature
fluorescence of PVpf_NP inside the HepG2 cells; HC stands for
heat-treated loaded F-virosomes. This experiment was repeated four
times and was highly reproducible.
of PVpf-NP, we performed additional experiments (Fig. 4).
Fig. 4 shows fluorescence microscopy images for the presence
of PVpf-NP inside the HepG2 cells as a result of virosome-
mediated delivery in a time-dependent manner (panel A). The
release kinetics of FITC-Dx from PVpf-NP was compared
with the delivery of free FITC-Dx through virosomes (diffuse
pattern fluorescence, panel B). The intactness ofPVpf-NP was
visualized in the form of punctate pattern of FITC fluores-
cence (arrows) until 6 h post-delivery inside the target cells.
Complete release of FITC-Dx from the NPs was observed 9 h
post-incubation of HepG2 cells with F-virosomes (cells in
panels A and B appeared same) as was confirmed by the
absence of any punctate pattern fluorescence. HepG2 cells
incubated with heat-treated loaded F-virosomes revealed no
detectable fluorescence. The release kinetics of FITC-Dx from
NPs appeared to be a slow and well-regulated phenomenon
amidst the complex cytosolic milieu of target cells.
4. Discussion
In recent years, encapsulation of potent cytotoxic drugs
(both hydrophilic and hydrophobic) inside polymeric hydrogel
NPs has been proven useful for reducing the toxicity and
influencing controlled release of such drugs at the site of ac-
tion [1,4,17]. However, targeting of such drug-loaded NPs to
various cell types both in vitro and in vivo has not yet been
precisely achieved [18]. In spite of limited success in conferring
cell/tissue specificity on the nanoparticulate surface [I], their
in vivo application in targeted drug delivery is severely im-
peded by the degradation of the polymer at the amide link-
ages by serum proteases [2]. To circumvent these major ob-
stacles, we have investigated the role of F-virosome in the
membrane-fusion-mediated transfer of a model drug-loaded
NP to the cytosol of HepG2 cells. The targeted nature of
this carrier is apparent from the inability of loaded F-viro-
somes in transferring PVpf-NPs to the NIH3T3 andCHG
cells (ASGP-R-deficient cell lines). Involvement of plasma
membrane level fusion of virosomes with HepG2 cells is con-
firmed from the failure of azide in inhibiting this transfer pro-
cess. Heat-treatment of F-virosomes and incubation with spe-
cific antibody against F protein are known to completely
abolish the fusogenicity of F protein [5-7,13,19]. Very low
internalization of PVpf -NP by heat-treated F-virosomes
(and F-virosomes pre-incubated with anti-F antibody) with
and without the presence of azide reflects the specificity of
this assay. Collectively, these observations corroborate the
role of F glycoprotein in specific binding and fusion of a
genetically modified Sendai virion and a Sendai mutant (defi-
cient in hemagglutinin-neuraminidase protein) with 1-7-1 cells
(NIH3T3 cells stably expressing ASGP-R on the cell surface)
and HepG2 cells respectively, as demonstrated earlier [19,20].
The cytosolic delivery of PVpf-NPs is further ascertained
from their subcellular distribution pattern (> 60% in the cy-
tosol) as compared to their heat-treated (ca. 21% in the cyto-
sol) counterparts. Most convincing evidence in support of
cyt solic delivery of intact PVpf -NP is revealed from the
punctate pattern of fluorescence in HepG2 cells over a diffuse
pattern of free FITC-Dx fluorescence in the presence of azide
(a potent inhibitor of endocytosis). Although the size of PVpf_
NPs is below the detection limit of the light microscope, the
presence of aggregated NPs produce images (punctate pat-
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tern) which are within the range of camera systems. This in-
ference is bolstered by our earlier observations on the inter-
action of FITC-Iabeled and octadecylrhodamine B-Iabeled
intact influenza virions with human RBCs [15,21]. Addition-
ally, the delivered PVpf-NP retained its integrity (punctate
pattern) in terms of holding the entrapped FITC-Dx until
6 h. This conclusion was further supported from the ultra-
centrifugation analysis of cytosolic fractions containing intact
PVpf-NP.
In essence, we have judiciously combined the power of vi-
rosomal and nanoparticulate drug delivery systems in design-
ing a novel and efficient hybrid vector to transfer a model
drug inside the cytosol of liver cells in culture. As an imme-
diate consequence, the virosome-associated NPs remain pro-
tected from degradation by proteases present in the culture
media until they are delivered to the cytosol of target cells. On
the other hand, once present in the cytosol the NPs mediate
slow and controlled release of the entrapped drugs. Therefore,
we envisage a potential application of this hybrid vector in
vivo in targeting appropriate anti-cancer drugs to liver cells.
The NP-mediated slow release of drugs in cytosol is one of the
coveted goals in treating liver cancer associated with multi-
drug resistance [22]. Moreover, technology is available in our
laboratory to encapsulate several hydrophobic anti-cancer
drugs in nanoparticulate carriers [17,23] that can be in turn
delivered to the cytosol of hepatocytes through F-virosomes.
Further work is needed to extrapolate this study in delivering
drug-loaded NPs to liver cells in whole animal through such
virosomal formulations.
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